Thirty-two studies on multi-omic biomarkers will debut at ASCO 2026. Caris Life Sciences leverages AI to analyze real-world evidence and precision oncology data. These findings aim to refine patient selection for targeted therapies. The volume of data is high, but the clinical impact remains incremental for most practitioners.